Especially given it is progressing a phase 3 trial towards a near term readout, it’s not like it’s a boring stock simply promising a high single digit or low double digit growth and a dividend each year. There are serious catalysts in the near term pipeline. What’s the bet if Vitiligo was the company’s sole asset and it was currently loss making, the market would be currently pushing it towards a $1billion market cap as you see with so many other biotechs? Sometimes it feels as if as soon a company starts making money, the market forgets about all the pre-revenue assets (that in this case are many multiples larger than EPP) and focuses instead on the asset that is making money, valuing nothing else but that.
What will happen when we get approval for Vitiligo, and sales quadruple in a year?
CUV Price at posting:
$12.14 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)